Squarepoint’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Squarepoint’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-33,095	Closed	-$607K	–	4679
2023 Q3	$607K	Buy	33,095 +19,635	+146%	+$411K	﹤0.01%	2647
2023 Q2	$349K	Sell	13,460 -29,949	-69%	-$699K	﹤0.01%	2869
2023 Q1	$819K	Buy	43,409 +28,110	+184%	+$654K	﹤0.01%	2017
2022 Q4	$377K	Buy	15,299 +732	+5%	+$21.5K	﹤0.01%	2453
2022 Q3	$261K	Sell	14,567 -62,708	-81%	-$1.13M	﹤0.01%	2564
2022 Q2	$877K	Buy	77,275 +65,757	+571%	+$967K	﹤0.01%	1692
2022 Q1	$257K	Buy	+11,518	New	+$294K	﹤0.01%	2366

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint's INBX Position: Q4 2023 in Review

Squarepoint sold out of Inhibrx, Inc. Common Stock (INBX) in Q4 2023, closing a stake of 33,095 shares — an estimated $607K sold.

Squarepoint first reported a position in INBX in Q1 2022 and held it in 7 quarters. The position peaked at $877K in Q2 2022. 127 funds tracked by Wall St. Rank hold INBX as of Q4 2023.

Squarepoint reported no remaining Inhibrx, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Squarepoint sold 33,095 Inhibrx, Inc. Common Stock shares in Q4 2023, an estimated $607K.
Squarepoint first reported a position in Inhibrx, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Squarepoint's Inhibrx, Inc. Common Stock position peaked at $877K in Q2 2022.
127 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q4 2023.

Based on Squarepoint's 13F filing for Q4 2023, filed 14 Feb 2024.